Overview
InvestingPro’s Fair Value analysis, published in January 2026, identified CytomX Therapeutics, Inc. (NASDAQ:CTMX) as significantly overvalued when the stock was trading at $5.73 per share. The model calculated an intrinsic fair value of $3.45, implying a potential downside of roughly 35% from the market price.
Stock Performance
Over the subsequent six‑month period, CytomX’s share price declined steadily, culminating in a 45.78% drop to $3.10 per share as of July 31, 2026. The decline validated InvestingPro’s forecast, delivering the predicted downside and exceeding it slightly.
Financial Fundamentals
At the time of the January assessment, CytomX reported revenue of $76.2 million, an EBITDA loss of $18.2 million, and earnings per share of –$0.15. By the end of July, revenue had contracted to $35.5 million, EBITDA losses had expanded to $60.6 million, and EPS deteriorated to –$0.39. The company also recorded negative free cash flow of $86.5 million and had reduced its workforce by approximately 40%.
Operational Highlights
During the same period, CytomX received a $37 million payment from Regeneron and announced encouraging trial data for its Varseta‑M candidate. Despite these positive developments, the underlying financial weaknesses persisted, and the stock continued its downward trajectory.
Methodology Note
InvestingPro’s Fair Value methodology combines discounted cash flow models, comparable company analyses, and analyst consensus targets, incorporating margin‑of‑safety considerations and forward cash‑flow projections to assess intrinsic worth. The CytomX case illustrates how systematic valuation can flag mispricing before market corrections occur.
Publication Details
The article, sourced from Reuters, was published on 02‑08‑2026 at 04:34 pm.